BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El‐shamy A, Nagano‐fujii M, Sasase N, Imoto S, Kim S, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008;48:38-47. [DOI: 10.1002/hep.22339] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. PLoS One 2018;13:e0198642. [PMID: 29856885 DOI: 10.1371/journal.pone.0198642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
2 Rajyaguru S, Yang H, Martin R, Miller MD, Mo H. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates. Antiviral Res 2013;100:328-36. [PMID: 24013002 DOI: 10.1016/j.antiviral.2013.08.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kato N, Sejima H, Ueda Y, Mori K, Satoh S, Dansako H, Ikeda M. Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems. PLoS One 2014;9:e91156. [PMID: 24625789 DOI: 10.1371/journal.pone.0091156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
4 Perales C, Beach NM, Sheldon J, Domingo E. Molecular basis of interferon resistance in hepatitis C virus. Current Opinion in Virology 2014;8:38-44. [DOI: 10.1016/j.coviro.2014.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
5 Gray RR, Parker J, Lemey P, Salemi M, Katzourakis A, Pybus OG. The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol Biol 2011;11:131. [PMID: 21595904 DOI: 10.1186/1471-2148-11-131] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 10.5] [Reference Citation Analysis]
6 Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin. Arch Virol 2013;158:1907-15. [DOI: 10.1007/s00705-013-1687-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012;55:231-241. [PMID: 21734353 DOI: 10.1159/000328327] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
8 Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011;54:1094-1101. [PMID: 21145800 DOI: 10.1016/j.jhep.2010.09.019] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 6.9] [Reference Citation Analysis]
9 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M. Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One. 2011;6:e24514. [PMID: 21935415 DOI: 10.1371/journal.pone.0024514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
10 Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. J Gastroenterol. 2012;47:1143-1151. [PMID: 22441534 DOI: 10.1007/s00535-012-0578-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
11 Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, Sakamoto M. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360-367. [PMID: 24612030 DOI: 10.1111/hepr.12316] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
12 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
13 Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol 2011;46:545-55. [PMID: 21246384 DOI: 10.1007/s00535-010-0358-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52:421-429. [PMID: 20648473 DOI: 10.1002/hep.23690] [Cited by in Crossref: 209] [Cited by in F6Publishing: 188] [Article Influence: 19.0] [Reference Citation Analysis]
15 Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol 2012;47:1014-21. [PMID: 22382633 DOI: 10.1007/s00535-012-0560-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
16 Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol 2013; 19(2): 284-289 [PMID: 23345952 DOI: 10.3748/wjg.v19.i2.284] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
17 Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. Best Pract Res Clin Gastroenterol. 2012;26:413-427. [PMID: 23199501 DOI: 10.1016/j.bpg.2012.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
18 Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res. 2013;43:1-34. [PMID: 23332085 DOI: 10.1111/hepr.12020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
19 Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
20 Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J Clin Microbiol 2014;52:193-200. [PMID: 24197875 DOI: 10.1128/JCM.02371-13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
21 El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One. 2012;7:e30513. [PMID: 22319571 DOI: 10.1371/journal.pone.0030513] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
22 Sharma SD. Hepatitis C virus 1b viral factors (core, NS3, and NS5A) and increased risk of hepatocellular carcinoma: SHARMA. Hepatology 2013;58:491-3. [DOI: 10.1002/hep.26362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 ElHefnawi MM, Zada S, El-Azab IA. Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a. Virol J. 2010;7:130. [PMID: 20550652 DOI: 10.1186/1743-422x-7-130] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
24 Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20(11): 2902-2912 [PMID: 24659881 DOI: 10.3748/wjg.v20.i11.2902] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
25 Kan T, Hashimoto S, Kawabe N, Murao M, Nakano T, Shimazaki H, Nakaoka K, Ohki M, Takagawa Y, Kurashita T, Takamura T, Yoshioka K. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J Gastroenterol 2016;51:63-70. [DOI: 10.1007/s00535-015-1080-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
26 Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouso K, Iwasaki Y. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro. Liver Int. 2010;30:1324-1331. [PMID: 20602680 DOI: 10.1111/j.1478-3231.2010.02299.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
27 Glisic S, Veljkovic N, Jovanovic Cupic S, Vasiljevic N, Prljic J, Gemovic B, Perovic V, Veljkovic V. Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. Protein J 2012;31:129-36. [DOI: 10.1007/s10930-011-9381-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8:e58380. [PMID: 23505497 DOI: 10.1371/journal.pone.0058380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Abdel-Aty M, Fouad M, Sallam MM, Elgohary EA, Ismael A, Nawara A, Hawary B, Tag-Adeen M, Khaled S. Incidence of HCV induced-Esophageal varices in Egypt: Valuable knowledge using data mining analysis. Medicine (Baltimore) 2017;96:e5647. [PMID: 28121921 DOI: 10.1097/MD.0000000000005647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Torti C, Zazzi M, Abenavoli L, Trapasso F, Cesario F, Corigliano D, Cosco L, Costa C, Curia RL, De Rosa M. Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). BMC Infect Dis. 2012;12 Suppl 2:S9. [PMID: 23173812 DOI: 10.1186/1471-2334-12-s2-s9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
31 Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009;44:1009-1015. [PMID: 19756352 DOI: 10.1007/s00535-009-0126-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
32 Kuznetsova T, Tallo T, Brjalin V, Reshetnjak I, Salupere R, Priimagi L, Katargina O, Smirnova M, Jansons J, Tefanova V. Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response. Hepat Mon 2013;13:e14481. [PMID: 24358043 DOI: 10.5812/hepatmon.14481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Arakawa T, Fujimori M, Niinomi T, Ando N, Yasuda S, Sakai K, Kimura J. High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. J Gastroenterol 2011;46:501-9. [PMID: 20927636 DOI: 10.1007/s00535-010-0328-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
34 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
35 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology. 2012;55:417-425. [PMID: 21325786 DOI: 10.1159/000323526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
36 El Hefnawi MM, El Behaidy WH, Youssif AA, Ghalwash AZ, El Housseiny LA, Zada S. Natural genetic engineering of hepatitis C virus NS5A for immune system counterattack. Ann N Y Acad Sci. 2009;1178:173-185. [PMID: 19845637 DOI: 10.1111/j.1749-6632.2009.05003.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
37 Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848 [PMID: 26668696 DOI: 10.4254/wjh.v7.i28.2841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
38 Laufer N, Bolcic F, Rolón MJ, Martinez A, Reynoso R, Pérez H, Salomón H, Cahn P, Quarleri J. HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antiviral Res 2011;90:92-7. [PMID: 21376083 DOI: 10.1016/j.antiviral.2011.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
39 El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol. 2012;50:3886-3892. [PMID: 22993188 DOI: 10.1128/jcm.02109-12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
40 Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T, Maehara Y. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. J Viral Hepat 2014;21:397-404. [PMID: 24750545 DOI: 10.1111/jvh.12154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
41 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 12.7] [Reference Citation Analysis]
42 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Inada Y, Uto H, Hiramine Y, Kure T, Fujisaki K, Hashiguchi M, Hori T, Oshige A, Imanaka D, Saishoji A, Taniyama O, Sakae H, Tamai T, Moriuchi A, Ido A. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. J Gastroenterol 2017;52:855-67. [DOI: 10.1007/s00535-016-1303-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
43 Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Maehara Y. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol. 2010;52:672-680. [PMID: 20346532 DOI: 10.1016/j.jhep.2009.10.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
44 Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30:1259-1269. [PMID: 20633102 DOI: 10.1111/j.1478-3231.2010.02283.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 11.2] [Reference Citation Analysis]
45 Gonzalez VD, Falconer K, Björkström NK, Blom KG, Weiland O, Ljunggren HG, Alaeus A, Sandberg JK. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol. 2009;183:6612-6618. [PMID: 19846870 DOI: 10.4049/jimmunol.0901437] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 8.0] [Reference Citation Analysis]
46 Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol. 2013;87:7593-7607. [PMID: 23637397 DOI: 10.1128/jvi.02824-12] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
47 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol. 2012;84:1097-1105. [PMID: 22585728 DOI: 10.1002/jmv.23262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
48 El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. Microbiol Immunol. 2011;55:418-426. [PMID: 21371092 DOI: 10.1111/j.1348-0421.2011.00331.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
49 Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int. 2012;6:386-396. [PMID: 22020823 DOI: 10.1007/s12072-011-9307-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
50 Khaliq S, Latief N, Jahan S. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. Arch Virol. 2014;159:1-15. [PMID: 23851652 DOI: 10.1007/s00705-013-1780-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
51 Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952-963. [PMID: 19517057 DOI: 10.1007/s00535-009-0087-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
52 Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasegawa Y, Fujinami A, Ohta M, El-shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Hotta H, Kudo M. Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy. Digestion 2011;84:10-6. [DOI: 10.1159/000333209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Kawai Y, Ikeda M, Abe K, Yano M, Ariumi Y, Dansako H, Yamamoto K, Kato N. Development of a hepatitis C virus relapse model using genome-length hepatitis C virus ribonucleic acid-harboring cells possessing the interferon-α-resistance phenotype. Hepatology Research 2009;39:898-909. [DOI: 10.1111/j.1872-034x.2009.00525.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Chen CH, Yu ML. Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat. 2010;2010:140953. [PMID: 21152178 DOI: 10.1155/2010/140953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
55 Kudo M. Tailor-made therapy for viral hepatitis: recent advances. Digestion 2011;84 Suppl 1:1-4. [PMID: 22156478 DOI: 10.1159/000333207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
56 Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M Jr, Lee WM. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis 2009;200:866-76. [PMID: 19673650 DOI: 10.1086/605475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
57 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J Med Virol. 2013;85:1028-1036. [PMID: 23588728 DOI: 10.1002/jmv.23579] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
58 Sato M, Maekawa S, Komatsu N, Tatsumi A, Miura M, Muraoka M, Suzuki Y, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Uetake T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J Virol. 2015;89:6105-6116. [PMID: 25810555 DOI: 10.1128/jvi.03127-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
59 Schweitzer CJ, Liang TJ. Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol 2013;3:501-7. [PMID: 23835049 DOI: 10.1016/j.coviro.2013.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
60 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol. 2010;82:575-582. [PMID: 20166188 DOI: 10.1002/jmv.21741] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
61 Kamada K, Shoji I, Deng L, Aoki C, Ratnoglik SL, Wakita T, Hotta H. Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production. Microbes Infect 2012;14:69-78. [PMID: 21917232 DOI: 10.1016/j.micinf.2011.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
62 Kozuka R, Enomoto M, Hai H, Ogawa T, Nakaya M, Hagihara A, Fujii H, Kobayashi S, Iwai S, Morikawa H, Tamori A, Kawada N. Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment. Hepatol Res 2012;42:1157-67. [PMID: 22672644 DOI: 10.1111/j.1872-034X.2012.01046.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
63 Seronello S, Montanez J, Presleigh K, Barlow M, Park SB, Choi J. Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals. PLoS One 2011;6:e27436. [PMID: 22087316 DOI: 10.1371/journal.pone.0027436] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
64 Yokoyama K, Takahashi M, Nishizawa T, Nagashima S, Jirintai S, Yotsumoto S, Okamoto H, Momoi MY. Identification and characterization of a natural inter-genotypic (2b/1b) recombinant hepatitis C virus in Japan. Arch Virol 2011;156:1591-601. [DOI: 10.1007/s00705-011-1038-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
65 Xiang X, Lu J, Dong Z, Zhou H, Tao W, Guo Q, Zhou X, Bao S, Xie Q, Zhong J. Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. Infect Genet Evol 2011;11:382-90. [PMID: 21147266 DOI: 10.1016/j.meegid.2010.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
66 Qi H, Chu V, Wu NC, Chen Z, Truong S, Brar G, Su SY, Du Y, Arumugaswami V, Olson CA, Chen SH, Lin CY, Wu TT, Sun R. Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A 2017;114:2018-23. [PMID: 28159892 DOI: 10.1073/pnas.1614623114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
67 El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, Hotta H. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology. 2012;55:1-11. [PMID: 21293098 DOI: 10.1159/000322219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
68 Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, Ben Mami N, Triki H, Chouchane L. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy. J Med Virol 2009;81:2021-8. [PMID: 19856481 DOI: 10.1002/jmv.21641] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
69 Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology. 2012;56:1611-1621. [PMID: 22577043 DOI: 10.1002/hep.25826] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
70 Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada S, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int 2012;6:482-90. [PMID: 22020822 DOI: 10.1007/s12072-011-9306-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
71 El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma. Hepatology. 2013;58:555-563. [PMID: 23281009 DOI: 10.1002/hep.26205] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
72 Sasayama M, Shoji I, Adianti M, Jiang DP, Deng L, Saito T, Watanabe H, Kawata S, Aoki C, Hotta H. A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization. J Med Virol 2012;84:229-34. [PMID: 22170542 DOI: 10.1002/jmv.22257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
73 Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Fukuhara T, Kotoh K, Shimoda S, Kato M, Maehara Y. The Benefits of Interferon Treatment in Patients Without Sustained Viral Response After Living Donor Liver Transplantation for Hepatitis C. Transplantation Proceedings 2009;41:4246-52. [DOI: 10.1016/j.transproceed.2009.08.070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
74 Ochi H, Miki D, Hayes CN, Abe H, Hayashida Y, Kubo M, Chayama K. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. J Gen Virol 2014;95:1297-306. [PMID: 24646752 DOI: 10.1099/vir.0.060103-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
75 Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-368. [PMID: 20394674 DOI: 10.1111/j.1872-034x.2010.00642.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
76 Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy: SNP of IL28B, HCV core, NS5A genotype 1b and Peg-IFN+RBV. Liver International 2011;31:1359-65. [DOI: 10.1111/j.1478-3231.2011.02571.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
77 Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352-354. [PMID: 22658798 DOI: 10.1016/j.jcv.2012.04.024] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 10.3] [Reference Citation Analysis]
78 Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
79 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81:452-458. [PMID: 19152407 DOI: 10.1002/jmv.21400] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
80 Li H, Hughes AL, Bano N, McArdle S, Livingston S, Deubner H, McMahon BJ, Townshend-Bulson L, McMahan R, Rosen HR, Gretch DR. Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One 2011;6:e19562. [PMID: 21573177 DOI: 10.1371/journal.pone.0019562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
81 Sanjo M, Saito T, Ishii R, Nishise Y, Haga H, Okumoto K, Ito J, Watanabe H, Saito K, Togashi H. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol. 2010;82:1364-1370. [PMID: 20572079 DOI: 10.1002/jmv.21818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
82 Mansoor A, Ali L, Sabah NU, Hashmi AH, Khan MH, Kazmi SA, Ahmad N, Siddiqi S, Khan KM. Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population. Virol J. 2013;10:352. [PMID: 24321105 DOI: 10.1186/1743-422x-10-352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 El Awady MK, Bader El Din NG, Tabll A, El Hosary Y, Abdel Aziz AO, El Khayat H, Salama M, Abdelhafez TH. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol 2013; 19(2): 290-298 [PMID: 23345953 DOI: 10.3748/wjg.v19.i2.290] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
84 Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C: Factors for difficult-to-treat HCV patients. Hepatology Research 2010;40:1155-67. [DOI: 10.1111/j.1872-034x.2010.00726.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
85 Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577-1585, 1585.e1-3. [PMID: 20708617 DOI: 10.1053/j.gastro.2010.07.058] [Cited by in Crossref: 173] [Cited by in F6Publishing: 160] [Article Influence: 15.7] [Reference Citation Analysis]
86 Belema M, Lopez OD, Bender JA, Romine JL, St Laurent DR, Langley DR, Lemm JA, O'Boyle DR 2nd, Sun JH, Wang C, Fridell RA, Meanwell NA. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem. 2014;57:1643-1672. [PMID: 24621191 DOI: 10.1021/jm401793m] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
87 Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol. 2011;26 Suppl 1:83-95. [PMID: 21199518 DOI: 10.1111/j.1440-1746.2010.06550.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
88 Enomoto H, Nishiguchi S. Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. World J Hepatol 2015; 7(26): 2681-2687 [PMID: 26609345 DOI: 10.4254/wjh.v7.i26.2681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
89 Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. J Clin Microbiol. 2013;51:2862-2868. [PMID: 23784126 DOI: 10.1128/jcm.01129-13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
90 Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res 2015;45:1292-8. [PMID: 25689487 DOI: 10.1111/hepr.12505] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
91 Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. J Viral Hepat. 2011;18:280-286. [PMID: 20367792 DOI: 10.1111/j.1365-2893.2010.01305.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
92 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M. Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. Hepatol Int. 2011;5:789-799. [PMID: 21484117 DOI: 10.1007/s12072-011-9267-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
93 Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B: PEG IFN for low HCV patients and ISDR and IL-28B. Hepatol Res 2013;43:580-8. [DOI: 10.1111/hepr.12005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Kumthip K, Pantip C, Chusri P, Thongsawat S, O’Brien A, Nelson KE, Maneekarn N. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat. 2011;18:e117-e125. [PMID: 20955493 DOI: 10.1111/j.1365-2893.2010.01379.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
95 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
96 Sato K, Hashizume H, Yamazaki Y, Horiguchi N, Kakizaki S, Takagi H, Mori M; Gunma Liver Study Group. Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads. Hepatol Res. 2012;42:854-863. [PMID: 22487210 DOI: 10.1111/j.1872-034x.2012.00997.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
97 Roche B, Samuel D. Are viral or host factors predictive of response to interferon–ribavirin in transplant patients with hepatitis C? Journal of Hepatology 2010;52:630-2. [DOI: 10.1016/j.jhep.2010.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Kamatani N, Chayama K. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011;83:1597-607. [PMID: 21739451 DOI: 10.1002/jmv.22158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]